Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
|Articles|December 2, 2021
Daily Medication Pearl: Dronabinol (Marinol)
Author(s)Saro Arakelians, PharmD
Marinol is a cannabinoid indicated for anorexia associated with weight loss in patients with AIDS.
Advertisement
Medication Pearl of the Day: Dronabinol (Marinol)
Indication: Marinol is a cannabinoid indicated in adults for the treatment of anorexia associated with weight loss in patients with AIDS.
Insight:
- Dosing: The recommended adult starting dosage is 2.5 mg orally twice daily, 1 hour before lunch and dinner.
- Dosage forms: Capsules: 2.5 mg, 5 mg, 10 mg.
- Adverse events (AEs): Most common AEs are abdominal pain, dizziness, euphoria, nausea, paranoid reaction, somnolence, thinking abnormal, and vomiting.
- Mechanism of action: Dronabinol is an orally active cannabinoid, which has complex effects on the central nervous system, including central sympathomimetic activity
- Manufacturer: AbbVie
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Advertisement
Advertisement